James T Fandl

US Patent:

6472178, Oct 29, 2002

Filed:

Feb 27, 1998

Appl. No.:

09/031693

Inventors:

James P. Fandl - Lagrangeville NY
Neil E. Stahl - Carmel NY
Stanley J. Wiegand - Ossining NY

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 1518

US Classification:

435 694, 4353201, 435325, 4352523, 536 2351

Abstract:

Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntingtons disease, obesity, and gestational or adult onset diabetes.

US Patent:

6919183, Jul 19, 2005

Filed:

Jan 16, 2002

Appl. No.:

10/050279

Inventors:

James P. Fandl - LaGrangeville NY, US
Neil Stahl - Carmel NY, US
Gang Chen - Yorktown Heights NY, US
George D. Yancopoulos - Yorktown Heights NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

G01N033/53
C12N015/09
C12N021/02
C12N021/08

US Classification:

435 72, 435 693, 435 694, 435 697, 435 701, 435 702, 435 7021, 435 703, 435 711

Abstract:

A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.

US Patent:

7087411, Aug 8, 2006

Filed:

Jun 30, 2003

Appl. No.:

10/609775

Inventors:

Thomas J. Daly - New City NY, US
James P. Fandl - LaGrangeville NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C07H 21/04
C07K 14/71
C12N 15/12
C12P 21/02
A61K 38/16

US Classification:

435 697, 530350, 530399, 4352523, 4353201, 536 234

Abstract:

Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF mini-traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.

US Patent:

7119066, Oct 10, 2006

Filed:

Oct 28, 2002

Appl. No.:

10/281643

Inventors:

James P. Fandl - Lagrangeville NY, US
Neil E. Stahl - Carmel NY, US
Stanley J. Wiegand - Croton-on-Hudson NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C07K 14/475
A61K 38/18

US Classification:

514 12, 530399

Abstract:

Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or adult onset diabetes.

US Patent:

7279159, Oct 9, 2007

Filed:

Jun 29, 2004

Appl. No.:

10/880021

Inventors:

Thomas J. Daly - New City NY, US
James P. Fandl - Lagrangeville NY, US
Nicholas J. Papadopoulos - Lagrangeville NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 38/18
C07K 14/71
C12N 15/62

US Classification:

4241341, 4241921, 435 697, 514 2, 514 12, 530350, 5303873, 536 234

Abstract:

Nucleic acid molecules and multimeric proteins capable of binding vascular endothelial growth factor (VEGF). VEGF traps are disclosed which are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.

US Patent:

7303747, Dec 4, 2007

Filed:

Sep 1, 2005

Appl. No.:

11/218234

Inventors:

Stanley J. Wiegand - Croton-on-Hudson NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
George D. Yancopoulos - Yorktown Heights NY, US
James P. Fandl - LaGrangeville NY, US
Thomas J. Daly - New City NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 38/18
C07K 14/71
C12N 15/62

US Classification:

4241341, 4241921, 514 2, 514 12, 530350, 536 234

Abstract:

Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.

US Patent:

7306799, Dec 11, 2007

Filed:

Mar 25, 2005

Appl. No.:

11/089803

Inventors:

Stanley J. Wiegand - Croton on Hudson NY, US
Nicholas J. Papadopoulos - LaGrangeville NY, US
George D. Yancopoulos - Yorktown Heights NY, US
James P. Fandl - LaGrangeville NY, US
Thomas J. Daly - New City NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

A61K 38/18
C07K 14/71
C12N 15/62

US Classification:

4241341, 4241921, 514 2, 514 12, 530350, 536 234

Abstract:

Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.

US Patent:

7399612, Jul 15, 2008

Filed:

Feb 2, 2006

Appl. No.:

11/346008

Inventors:

Thomas J. Daly - New City NY, US
James P. Fandl - Lagrangeville NY, US
Nicholas J. Papadopoulos - Lagrangeville NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 15/62
C12N 15/63
A61K 38/18
C07K 14/00
C07K 14/71

US Classification:

435 697, 4241341, 4241921, 435 711, 4352523, 4353201, 435325, 435358, 514 2, 514 12, 530350, 5303873, 536 234

Abstract:

Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.